Slide 1: Financial results of the Diagnostyka Group for Q2 2026
Financial results of the Diagnostyka Group for Q2 2026 11 September 2026
Slide 2: Presenters
Presenters: Jakub Swadźba Jakub Tatak Bartosz Cieślicki President of the Management Board, Vice President of the Management Deputy Chief Financial Officer Board, Chief Executive Officer (CEO) Chief Financial Officer (CFO)
Slide 3: Key developments in Q2 2026
Diagnosty! Key developments in Q2 2026
Slide 4: Q2 2026 summary
Q2 2026 summary Financial highlights Operational highlights Medical laboratory Revenue from Dividend paid by the testing services Penta Hospitals Recurring EBITDA¹ Company for 2025 contracts with Poland customers 2 acquisitions PLN 154.4 PLN 148.5 in Q2 2026 Increased contract value PLN 683.0 millio
Slide 5: Financial performance
Diagnosty! Financial performance
Slide 6: Dominant share of the MLT market in the Group's revenue in Q2 2026
Dominant share of the MLT market in the Group’s revenue in Q2 2026 Revenue from contracts with customers (PLN million) and share of the MLT and DI markets in the Group’s revenue 671 683 6.0% 612 618 6.3% 592 588 5.6% 6.1% 4.1% 4.7% 505 1.5% DI 93.7% 94.0% 6.0% 95.9% 95.3% 94.4% 93.9% 98.5% MLT Q4 20
Slide 7: Strong revenue growth driven by organic expansion
Strong revenue growth driven by organic expansion Revenue from contracts with customers (PLN million) + ROBUST REVENUE GROWTH MLT: +12.7% Revenue mix: MLT: +14.5% +14.8% The Group continued to deliver strong revenue growth, with revenue up 16.1% y/y (including 14.5% in MLT) in Q2 2026 and +16.1% 1,3
Slide 8: Revenue growth driven by both volume and pricing
Revenue growth driven by both volume and pricing Test volume (million) Volume mix +4.1% +2.6% Q2 2025 B2C + ACCELERATION IN VOLUME GROWTH IN Q2 2026 43.7 45.8 45.5 88.9 91.3 Following a temporary slowdown in Q1 2026, resulting from 0.276 0.377 14,8% 0.135 0.189 0.188 a high comparative base (the imp
Slide 9: Structure of operating expenses
Structure of operating expenses + STABILISATION OF THE NEW ERP SYSTEM (SAP) Operating expenses (PLN million) The new ERP system (SAP) went live in January 2026, requiring further y/y growth fine-tuning and optimisation of operating processes. In Q2 2026, work of operating expenses (%): 21.5% 15.7% 2
Slide 10: Recurring EBITDA at PLN 334.0 million in H1 2026, up 6.3% y/y
Recurring EBITDA at PLN 334.0 million in H1 2026, up 6.3% y/y Recurring EBITDA (PLN million) + Q2 2026 margin affected by SAP system stabilisation costs Recurring EBITDA 26.0% 26.8% 22.6% 26.6% 24.7% margin (%): + Other operating income in H1 2026 was supported by a PLN 4.3 million gain on fair valu
Slide 11: PLN 139.9 million net profit attributable to owners of the Parent
PLN 139.9 million net profit attributable to owners of the Parent Change % change % change Key factors driving net profit growth in H1 2026 vs Q2 2025 Q2 2026 H1 2025 H1 2026 Change y/y y/y y/y y/y H1 2025 (up PLN 4.5 million y/y): Recurring EBITDA 152.9 154.4 1.5 1.0% 314.1 334.0 19.9 6.3% Recurrin
Slide 12: Robust cash flow supporting the Group's further growth
Robust cash flow supporting the Group's further growth Free cash flow (PLN million) Capex (PLN million) Capex excl. FCF/EBITDA 107.3% 77.4% 79.6% 94.2% 78.4% 6.4% 4.1% 5.8% 5.9% 4.9% M&A/revenue IT INVESTMENTS: 30.2 million in H1 2025 vs 33.2 million in 106.4 108.1 H1 2026 -11.0% INVESTMENTS IN THE
Slide 13: Net debt and working capital under control
Net debt and working capital under control + Net working capital up PLN 71.0 million year on year in Q2 2026, with the increase due to a PLN 102.1 million growth in receivables, mainly as a result of higher sales + Increase in net debt to PLN 1,203.9 million, driven by higher lease liabilities (up P
Slide 14: 2026 outlook for the Diagnostyka Group
2026 outlook for the Diagnostyka Group Revenue from contracts low/mid teens % y/y growth with customers Average price per test high single digit % y/y growth Test volume low/mid single digit % y/y growth Recurring EBITDA margin close to 2025 Capex excl. M&A PLN 170-220 million M&A capex PLN 50-100 m
Slide 15: Appendices
Appendices
Slide 16: Half-year condensed consolidated statements of comprehensive income and financial position
Half-year condensed consolidated statement of Half-year condensed consolidated statement of financial position (PLN thousand) comprehensive income (PLN thousand) As at As at As at As at H1 2026 H1 2025 Change (%) Q2 2026 Q2 2025 Change (%) ASSETS Change (%) EQUITY AND LIABILITIES Change (%) 30 Jun 2
Slide 17: Half-year condensed consolidated statement of cash flows
Half-year condensed consolidated statement of cash flows (PLN thousand) 1 Jan–30 Jun 2026 1 Jan–30 Jun 2025 1 Jan–30 Jun 2026 1 Jan–30 Jun 2025 Profit (loss) before tax 187,275 183,670 Cash flows from financing activities Adjustments to profit before tax: 147,691 129,416 Non-controlling interest in
Slide 18: Contact
Contact Michał Błasiński Investor Relations Director michal.blasinski@diag.pl Disclaimer This presentation (the “Presentation”) has been prepared by Diagnostyka S.A. (“Diagnostyka”) to share selected information about the Diagnostyka Group (“Diagnostyka Group”) with shareholders, analysts, business